Ovarian Cancer Drug Study = Improvments in Survival
Dr. Maurie Markman, vice president for clinical research talks about a study done in Japan with Paclitaxel and Carboplatin a standard drug regimen for the treatment of Ovarian Cancer. The study results, published in The Lancet in September 2009 indicates that weekly Paclitaxel plus Carboplatin improved survival of women with epithelial ovarian cancer and may represent a new treatment option.
These are excellent news! It is really great that physicians are developing new methods in order to cure cancer, in this case is ovarian cancer but maybe in a future it could work for more cancers! There is more information on this topic at Symposier site available for physicians.